Omnicell, Inc.
NASDAQ:OMCLMedical - Healthcare Information Services
-$0.58 today
- Market cap
- $1.59B
- Beta
- 0.96
- P/E (TTM)
- 84.1
- EPS (TTM)
- $0.45
Volume 0.34M
Average 0.57M
OMCL Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Omnicell, Inc.NASDAQ: OMCL
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$33.3M, compared with $5.55M a year earlier. Trailing-twelve-month accounts receivables was $4.99M.
Context
- Accounts receivables amounted to 3.5% of revenue in FY2025, up 3.0 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$33.3M or moves back toward the trailing-twelve-month quarterly average of $1.25M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 41.42M USD
- Year-over-year change
- +928.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.42M | +928.1% |
| FY2024 | 2024-12-31 | (5M) | -112.9% |
| FY2023 | 2023-12-31 | 38.74M | +164.2% |
| FY2022 | 2022-12-31 | (60.36M) | -47.3% |
| FY2021 | 2021-12-31 | (40.97M) | — |
Accounts Receivables vs competitors
How OMCL compares with its peers on the latest reported figures
- OMCL's LTM Mar 2026 accounts receivables of $4.99M is the 10th largest of the 11 companies compared; the peer median is $12.19M.
- Its year-over-year change of +206.8% is the 6th highest of 11, against a peer median of +193.3%.
- Accounts receivables amounts to 0.4% of revenue for OMCL, versus a peer median of 4.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $70.81M | +361.4% | — | 9.0% | |
| LTM Jun 2026 | $68.62M | +351.8% | — | 11.1% | |
| LTM Jun 2026 | $53.11M | -1291.9% | -65.0% | 4.1% | |
| LTM Jun 2026 | $25.79M | +400.5% | — | 4.1% | |
| LTM Mar 2026 | $19.4M | +209.1% | — | 0.8% | |
| LTM Mar 2026 | $14.56M | +1796.8% | +131.9% | 30.0% | |
| LTM Sep 2026 | $12.31M | -2.1% | — | 4.6% | |
| LTM Mar 2026 | $12.07M | +71.3% | +46.5% | 4.3% | |
| LTM Apr 2026 | $6.91M | +177.6% | -3.0% | 1.4% | |
| LTM Mar 2026 | $4.99M | +206.8% | — | 0.4% | |
| LTM Mar 2026 | $0 | -100.0% | -40.5% | 0.0% | |
| Peer median (excluding OMCL) | $12.19M | +193.3% | -3.0% | 4.2% | |
Competitors are the stored peer set for OMCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 77.85M | 5.65M | (20.37M) | 12.53M | 2.05M |
| Depreciation & Amortization | 84.93M | 99.17M | 95.56M | 89.76M | 86.63M |
| Deferred Income Tax | (3.27M) | (37.32M) | (11.05M) | (14.86M) | (1.29M) |
| Stock-Based Compensation | 53.16M | 68.25M | 55.3M | 39.32M | 44.5M |
| Change in Working Capital | (3.34M) | (73.47M) | 43.67M | 58.33M | (8.33M) |
| Accounts Receivables | (40.97M) | (60.36M) | 38.74M | (5M) | 41.42M |
| Inventory | (25.7M) | (30.12M) | 38.02M | 5.39M | (11.23M) |
| Accounts Payables | 29.08M | (7.75M) | (17.53M) | 7.21M | (9.28M) |
| Other Working Capital | 34.24M | 24.76M | (15.56M) | 50.73M | (29.25M) |
| Other Non-Cash Items | 22.48M | 15.5M | 17.98M | 2.64M | 3.74M |
| Operating Cash Flow | 231.81M | 77.78M | 181.09M | 187.72M | 127.3M |
| Capital Expenditures | (28.97M) | (60.74M) | (41.47M) | (36.46M) | (40.42M) |
| Acquisitions (Net) | (354.16M) | 2.07M | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | (15.35M) | 0 | (10.4M) | (10.17M) |
| Other Investing Activities | (29.37M) | 15.35M | 0 | (5.93M) | (9.78M) |
| Investing Cash Flow | (412.5M) | (58.67M) | (55.02M) | (52.79M) | (60.36M) |
| Debt Repayment | 0 | 0 | (2.97M) | (225.46M) | (175M) |
| Common Stock Issued | 0 | 40.18M | 23.22M | 38.58M | 16.87M |
| Common Stock Repurchased | (16.29M) | (52.21M) | 0 | 0 | (77.6M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 63.65M | (8.93M) | 3.17M | (48.7M) | 17.42M |
| Financing Cash Flow | 47.36M | (20.95M) | 23.42M | (235.58M) | (218.32M) |
| Effect of Forex Changes | (974K) | (944K) | (1.35M) | (1.72M) | 3.8M |
| Net Change in Cash | (134.3M) | (2.79M) | 148.14M | (102.37M) | (147.58M) |
| Free Cash Flow | 202.84M | 17.04M | 139.62M | 151.26M | 86.89M |
Omnicell, Inc.
NASDAQ:OMCL
Intrinsic Alpha fair value
Locked
Current Price
$34.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.